Tissue-agnostic drug development approaches have their own set of scientific and financial considerations, but some drugmakers are taking on those challenges.
The South Korean companies have also agreed to work together on the development of exosome-based biomedical products including diagnostics and therapeutics.
The companies will combine their respective technologies to create a biomarker and companion diagnostic development service for pharmaceutical customers.
Researchers identified PTEN mutations, MAP kinase pathway alterations, and other features linked to anti-PD-1 response in individuals with the brain cancer.
Within the country's first whole-genome sequencing program, researchers hope to initially focus on identifying markers associated with hereditary diseases and cancer risk.
Biocept will offer patient data from its liquid biopsy tests to Prognos, who will apply artificial intelligence to ensure that patients receive correct therapies.
The researchers will not only explore tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.
Researchers have shown nanoparticles can enrich low molecular weight, low abundance plasma proteins that are hard to detect using standard proteomic workflows.
The company said its test is the first biomarker-based diagnostic for IBD that predicts long-term disease outcome in Crohn's disease and ulcerative colitis.
The researchers will combine genomic analysis with environmental and mobile device data from 1,200 participants to try to better understand the disease.
The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.
